Breaking News

Novavax Names Corporate Development SVP

May 7, 2014

Andreasson brings extensive biopharma ops experience

Sven Andreasson has been appointed senior vice president, Corporate Development at Novavax, effective June 2, 2014. Mr. Andreasson will be responsible for identifying and evaluating new strategic opportunities leveraging the company's core strengths and growth initiatives.
 
Mr. Andreasson has extensive experience in biopharmaceutical operations, executive management and strategic development. He has served as executive officer of Isconova AB in Uppsala, Sweden, an international vaccine adjuvant company acquired by Novavax in 2013, currently operating as Novavax AB. Prior to this role, Mr. Andreasson served as chief executive officer of Beta-Cell NV in Brussels, Belgium and as chief executive officer of Active Biotech AB in Lund, Sweden. He also held roles senior roles at Pharmacia Corp.
 
"My first serious interactions with Sven occurred during our negotiations to acquire Isconova AB. I was immediately impressed with him as a pragmatic and thoughtful business professional. It became readily apparent to me that Novavax would benefit from his extensive vaccine and pharmaceutical industry experience and insight," said Stan Erck, president and chief executive officer of Novavax. "I am very excited to have someone with Sven's experience help me and the entire management team to evaluate organic and non-organic opportunities to build this business and increase shareholder value."
 

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016